Richmond Owusu

Dr. Richmond Owusu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2024 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
JKJoseph Kazibwe
Joseph Kazibwe
MGMohamed Gad
Mohamed Gad
EAEmmanuella Abassah-Konadu
Emmanuella Abassah-Konadu
IAIvy Amankwah
Ivy Amankwah
RORichmond Owusu
Richmond Owusu
FRFrancis Ruiz
Francis Ruiz
Diabetes remains one of the four major causes of morbidity and mortality globally among non-communicable diseases (NCDs. It is predicted to increase in sub–Saharan Africa by over 50% by 2045. The aim of this study is to identify, map and estimate the burden of diabetes in Ghana, which is essential for optimising NCD country policy and understanding existing knowledge gaps to guide future research in this area. We followed the Arksey and O’Malley framework for scoping reviews. We searched electronic databases including Medline, Embase, Web of Science, Scopus, Cochrane and African Index Medicus following a systematic search strategy. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews was followed when reporting the results. A total of 36 studies were found to fulfil the inclusion criteria. The reported prevalence of diabetes at national level in Ghana ranged between 2.80%– 3.95%. At the regional level, the Western region reported the highest prevalence of diabetes: 39.80%, followed by Ashanti region (25.20%) and Central region at 24.60%. The prevalence of diabetes was generally higher in women in comparison to men. Urban areas were found to have a higher prevalence of diabetes than rural areas. The mean annual financial cost of managing one diabetic case at the outpatient clinic was estimated at GHS 540.35 (2021 US $194.09). There was a paucity of evidence on the overall economic burden and the regional prevalence burden. Ghana is faced with a considerable burden of diabetes which varies by region and setting (urban/rural). There is an urgent need for effective and efficient interventions to prevent the anticipated elevation in burden of disease through the utilisation of existing evidence and proven priority-setting tools like Health Technology Assessment (HTA).

4 February 2022 in Vaccine
Verified
Journal Article
Open access
JNJustice Nonvignon
Justice Nonvignon
RORichmond Owusu
Richmond Owusu
BABrian Asare
Brian Asare
AAAlex Adjagba
Alex Adjagba
YAYap Wei Aun
Yap Wei Aun
SRStephen C. Resch
Stephen C. Resch
This study estimated cost of COVID-19 vaccine introduction and deployment in Ghana. Using the WHO-UNICEF COVID-19 Vaccine Introduction and deployment Costing (CVIC) tool Ghana’s Ministry of Health Technical Working Group for Health Technology Assessment (TWG-HTA) in collaboration with School of Public Health, University of Ghana, organized an initial two-day workshop that brought together partners to deliberate and agree on input parameters to populate the CVIC tool. A further 2–3 days validation with the Expanded Program of Immunization (EPI) and other partners to finalize the analysis was done. Three scenarios, with different combinations of vaccine products and delivery modalities, as well as time period were analyzed. The scenarios included AstraZeneca (40%), Johnson & Johnson (J&J) (30%), Moderna, Pfizer, and Sputnik V at 10% each; with primary schedule completed by second half of 2021 (Scenario 1); AstraZeneca (30%), J&J (40%), Moderna, Pfizer, and Sputnik V at 10% each with primary schedule completed by first half of 2022 (Scenario 2); and equal distribution (20%) among AstraZeneca, J&J, Moderna, Pfizer, and Sputnik V with primary schedule completed by second half of 2022 (Scenario 3). The estimated total cost of COVID-19 vaccination ranges between $348.7 and $436.1 million for the target population of 17.5 million. These translate into per person completed primary schedule cost of $20.9–$26.2 and per dose (including vaccine cost) of $10.5–$13.1. Again, per person completed primary schedule excluding vaccine cost was $4.5 and $4.6, thus per dose excluding vaccine also ranged from $2.2 – $2.3. The main cost driver was vaccine doses, including shipping, which accounts for between 78% and 83% of total cost. Further, an estimated 8,437–10,247 vaccinators (non-FTEs) would be required during 2021–2022 to vaccinate using a mix of delivery strategies, accounting for 8–10% of total cost. These findings provide the estimates to inform resource mobilization efforts by government and other partners.

27 January 2025 in Cost Effectiveness and Resource Allocation
Verified
Journal Article
Open access
PDF file
RORichmond Owusu
Richmond Owusu
DPDakota Pritchard
Dakota Pritchard
LHLieke Fleur Heupink
Lieke Fleur Heupink
GGGodwin Gulbi
Godwin Gulbi
IAIvy Amankwah
Ivy Amankwah
EAEmmanuella Abassah-Konadu
Emmanuella Abassah-Konadu
Childhood cancer is not a high priority in health care financing for many countries, including in Ghana. Delayed care seeking and treatment abandonment, often due to the financial burden of care seeking to families, are common reasons for a relatively low overall survival (OS) in low-and middle-income countries. In this study, we analyzed the cost-effectiveness of extending health insurance coverage to children with Burkitt lymphoma (BL) in Ghana. We developed a Markov model in Microsoft Excel to estimate the costs and effects of BL treatment when National Health Insurance Scheme (NHIS) was provided compared to the status quo where NHIS does not cover care for childhood cancer. The analysis was undertaken from the societal and health system (payer) perspective. Both costs (measured in $) and effects, measured using disability adjusted life years (DALYs), were discounted at a rate of 3%. The time horizon was a lifetime. Probabilistic sensitivity analysis was done to assess uncertainty in the measurement of the incremental cost-effectiveness ratio (ICER). A budget impact analysis was undertaken from the perspective of the NHIS. In the base-case analysis, the intervention (NHIS reimbursed treatment) was less costly than current practice ($8,302 vs $9,558). The intervention was also more effective with less DALYs per patient than the standard of care (17.6 vs 23.33). The ICER was -$219 per DALY averted from societal perspective and $113 per DALY averted from health system perspective. The probabilistic sensitivity analysis showed that the intervention is likely to be both less costly and more effective than current practice in 100% of the 1,000 simulations undertaken. Providing health insurance coverage to children with BL is potentially cost-effective. The effectiveness and cost-savings relating to this strategy is driven by its positive impact on treatment initiation and retention. Based on this evidence, there has been a policy change where Ghana’s NHIS has prioritized financing for cancer treatment in children.

11 October 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RORichmond Owusu
Richmond Owusu
SBSerwaa Akoto Bawua
Serwaa Akoto Bawua
EKEmmanuel Bugyei Kwarteng
Emmanuel Bugyei Kwarteng
LBLeonard Baatiema
Leonard Baatiema
JNJustice Nonvignon
Justice Nonvignon
Introduction: The intersection of infectious diseases, such as HIV, with chronic conditions like hypertension and diabetes poses a significant challenge in global health. While advancements in antiretroviral therapy have transformed HIV into a manageable chronic condition, a growing number of individuals with HIV now grapple with coexisting non-communicable diseases, impacting their Health-Related Quality of Life (HRQoL). Despite strides in HIV care, there is a notable policy gap that undermines efforts to address HIV-associated co-morbidities, particularly hypertension and diabetes, especially efforts to improve access, early detection, and ultimately HRQoL for individuals with HIV and co-morbidities. This study seeks to explore policy interventions aimed at improving the quality of life of HIV patients with hypertension or diabetes. Methods: The study utilized a qualitative descriptive design to explore the experiences and perspectives of healthcare professionals and support staff regarding policy interventions for managing HIV patients with hypertension and/or diabetes co-morbidities in three regions of Ghana. The research was conducted in the Upper West, Ashanti, and Greater Accra regions among 11 participants, chosen purposively from professions involved in HIV patient care to understand their views on the implementation of policy interventions to HRQoL for individuals with HIV and co-morbidities. In-depth interviews were conducted face-to-face and tape-recorded. Thematic analysis approach was used to analyze the data. Results: The study involved 11 participants from three regions with varied years of experience. Implemented policies that potentially improve the HRQoL for individuals with HIV and co-morbidities involve support groups, home visits, provision of free drugs, and counselling. Barriers to policy implementation included non-adherence to medication, stigma, cost of non-communicable diseases (NCDs) medications, accessibility issues to NCDs services, lack of interest or understanding among implementers, and high staff turnover. Facilitators encompassed in-service training, guidelines in common platforms, knowledge sharing, external resources, regular check-ups, and motivational packages for patients. Conclusion: Individuals with HIV and comorbidities face complex challenges impacting their HRQoL, including emotional and financial dimensions. The study identifies critical policies and barriers, underscoring the need for tailored, patient-centered approaches. Facilitators like in-service training and regular check-ups offer actionable insights for effective policy implementation, emphasizing improved health outcomes for those with comorbid conditions. The study recommends integrated care approach and adherence support programs that address the unique challenges faced by people living with HIV.

20 April 2023 in medRxiv
Verified
Preprint
Open access
PDF file
MGMohamed Gad
Mohamed Gad
JKJoseph Kazibwe
Joseph Kazibwe
EAEmmanuella Abassah-Konadu
Emmanuella Abassah-Konadu
IAIvy Amankwah
Ivy Amankwah
RORichmond Owusu
Richmond Owusu
FRFrancis Ruiz
Francis Ruiz
Introduction Diabetes remains one of the four major causes of morbidity and mortality globally among non-communicable diseases (NCDs. It is predicted to increase in sub–Saharan Africa by over 50% by 2045. The aim of this study is to identify, map and estimate the burden of diabetes in Ghana, which is essential for optimising NCD country policy and understanding existing knowledge gaps to guide future research in this area. Methods We followed the Arksey and O’Malley framework for scoping reviews. We searched electronic databases including Medline, Embase, Web of Science, Scopus, Cochrane and African Index Medicus following a systematic search strategy. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews was followed when reporting the results. Results A total of 36 studies were found to fulfil the inclusion criteria. The reported prevalence of diabetes at national level in Ghana ranged between 2.80% – 3.95%. At the regional level, the Western region reported the highest prevalence of diabetes: 39.80%, followed by Ashanti region (25.20%) and Central region at 24.60%. The prevalence of diabetes was generally higher in women in comparison to men. Urban areas were found to have a higher prevalence of diabetes than rural areas. The mean annual financial cost of managing one diabetic case at the outpatient clinic was estimated at GHS 540.35 (2021 US $194.09). There was a paucity of evidence on the overall economic burden and the regional prevalence burden. Conclusion Ghana is faced with a considerable burden of diabetes which varies by region and setting (urban/rural). There is an urgent need for effective and efficient interventions to prevent the anticipated elevation in burden of disease through the utilisation of existing evidence and proven priority-setting tools like Health Technology Assessment (HTA).

7 April 2025 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
RORichmond Owusu
Richmond Owusu
EDEsther Esi Degbor
Esther Esi Degbor
DODesmond Dzidzornu Otoo
Desmond Dzidzornu Otoo
RARuby A. M. Annan
Ruby A. M. Annan
Managing HIV alongside chronic conditions such as hypertension and diabetes present significant economic challenges for households, especially in low-and middle-income countries. These chronic diseases not only reduce the quality of life of people living with HIV (PLHIV) but also further increase their economic burden. This study seeks to examine the economic burden of managing PLHIV with hypertension and diabetes comorbidities. The cross-sectional cost-of-illness study used quantitative data gathered from 56 PLHIV with hypertension and/or diabetes receiving ART at two Polyclinics and the Pentecost Hospital in the La Nkwantanang-Madina Municipality. A structured questionnaire was used to collect data on patients’ socio-demographic characteristics, direct, indirect, and intangible costs between September to December 2023. Data was analyzed and presented descriptively.The total economic cost of PLHIV managing comorbidities was GHS11,892.11 (USD 1,022.54) with a direct cost of GHS10,739.00 (US$ 923.39) accounting for 90.3% and indirect cost of GHS 1,153.14 (US$ 99.15) accounting for 9.7% over 6 months. Direct medical costs constituted 83.1% of total costs with the cost of medicines being the largest cost component. There was a significant difference between the total costs across the comorbidities (X2=8.58, p = 0.0137). Approximately 45.24% of the average annual income per person was spent on managing comorbidities in PLHIV. About 89% of participants reported a low intangible cost burden. This study reveals the significant economic burden on households managing HIV with hypertension and diabetes comorbidities. Direct costs driven by medication expenses constituted the majority of the burden, while productivity losses compounded indirect costs. Despite widespread health insurance coverage, substantial out-of-pocket payments are made in the management of these comorbidities. The findings emphasize the need for integrated healthcare strategies to address both communicable and non-communicable diseases, especially in low-income settings, and policies to reduce financial barriers. Studies should explore long-term burden and strategies to alleviate the economic impact on vulnerable populations.